Poolbeg Pharma has been granted a South Korean patent for its drug POLB 001, which targets prevention of cytokine release syndrome (CRS) in cancer immunotherapy. This patent extends protection until 2044 and adds to existing patents in Europe, Canada, South Africa, and Australia. The drug is currently being tested in the TOPICAL study for multiple myeloma patients receiving teclistamab, with positive interim safety results. Analysts maintain a 'buy' rating and see significant upside potential, supported by ongoing partnering talks and clinical progress that enhance POLB 001's commercial appeal.
Poolbeg Pharma's recent South Korean patent grant is notable context for readers following pharmaceutical innovation. For readers following health-sector stocks on Pluang, here is the market snapshot as of Oct 06, 2026 16:41 WIB: out of 100 priced US health-sector stocks, 69 rose and 23 fell. Among notable movers, Koninklijke Philips NV (PHG) rose 1.34% to USD 24.23 with 100% buy order activity, Viatris Inc (VTRS) increased 1.25% to USD 17.84, and Smith & Nephew plc (SNN) gained 1.23% to USD 27.25.
GM's third-quarter sales fell 5.5%, mainly due to a sharp drop in electric vehicle sales after a tax credit rush in 2025. Excluding EVs, sales slightly increased, showing GM is not deliberately limiting supply but focusing on pricing discipline. The ...
Nvidia's stock has grown dramatically over the past decade, turning a $10,000 investment into over $1.3 million. However, with a current market cap of $5.57 trillion, such exponential growth is unlikely to repeat. Analysts predict a 17.5% price incre...
A Santa Fe judge will soon decide how much Meta owes New Mexico after a jury found Meta liable for over 43 million data privacy violations related to the Cambridge Analytica scandal. The New Mexico Department of Justice demands between $35 billion an...
Over the past six months, Costco's stock has fallen by 10%, contrasting with the S&P 500's 17% gain. This decline has sparked debate on whether Costco's shares, now trading under $900, represent a buying opportunity. Investors are weighing if the pri...
The article explains a preference for the Vanguard S&P 500 ETF (VOO) over the Invesco QQQ Trust (QQQ) for long-term investing due to VOO's stability and quality filter. VOO excludes unprofitable and speculative firms, reducing risk compared to QQQ, w...
